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Abstract
The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a
major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard
therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM
and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients.
The existence of second generation TK inhibitors, which are effective in patients with IM resistance,
makes identification of predictors of resistance to IM an important goal in CML. In this study, we
have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with
newly diagnosed CML.
Introduction
The development of Imatinib Mesylate (IM), the first spe-
cific inhibitor of BCR-ABL1, has had a major impact in
patients with Chronic Myeloid Leukemia (CML) [1].
Treatment with IM induces a complete hematological and
cytogenetic response in more than 90 and 80% of newly
diagnosed patients with chronic phase CML respectively,
[2] which has established IM as the standard therapy for
CML. Despite the clinical success obtained with the use of
IM, primary resistance to IM and molecular evidence of
persistent disease has been observed in 20-25% of IM
treated patients [1]. Different mechanisms of resistance
have been described, including the presence of point
mutations in the tyrosine kinase domain of BCR-ABL1,
amplification and overexpression of BCR-ABL1, overex-
pression of efflux transporters (such as ABCB1, also
known as MDR1 or p-glycoprotein, and ABCG2) and
underexpression of uptake transporters (such as SLC22A1,
also known as hOCT1) [1]. However, it is currently
impossible to predict whether a patient will develop
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inhibitors, which are effective in patients with IM resist-
ance, makes identification of predictors of resistance to IM
an important goal in CML.
MicroRNAs (miRNAs) are non-coding, single-stranded
RNAs of 21-25 nucleotides that have recently been impli-
cated in the regulation of a number of biological processes
such as development, differentiation, apoptosis, prolifer-
ation and hematopoiesis. They regulate gene expression
by promoting degradation of the mRNA or repressing its
translation [3]. In addition, miRNAs have been impli-
cated in the development of human cancers, either as
tumor suppressors or as oncogenes. Aberrant miRNA
expression has recently been described for a variety of
solid tumors (lung, breast or colorectal cancer among oth-
ers) and hematological malignancies (chronic lym-
phocytic leukemia, B-cell lymphomas, acute
promyelocytic leukemias, acute lymphocytic leukemia
and CML). In CML, abnormal expression of several miR-
NAs has been described (miR-15a, miR-16, miR-142, miR-
155, miR-181, miR-221, let7a and the polycistronic miR-
17-92 cluster) [4-6] and we have currently demonstrated
that down-regulation of miR-10a leads to an abnormal
proliferation of CML cells through regulation of USF2
gene expression [3]. A role for microRNA expression as a
prognostic factor in various tumors has only been recently
described, [7] while no information is available regarding
their involvement in the response to chemotherapy.
Recent studies suggest that miR-15b and miR-16, and miR-
27a and miR-451 modulate multidrug resistance by target-
ing BCL2 and MDR1 respectively [8,9].
Findings
With the objective of deciphering a potential miRNA
expression signature associated with IM resistance, we
analyzed the expression profile of 250 miRNAs by Q-RT-
PCR using TaqMan methodology (PE Applied Biosystems,
Foster City, CA) using bone marrow mononuclear cells
from patients with Ph+ CML at diagnoses (n = 8). All
patients were treated with identical doses of IM (400 mg
daily) as first-line therapy. Three patients were considered
to be primary resistant (less than partial cytogenetic
response (Ph+ > 35%) after 12 months on IM; 400 mg/
day for the first six months and 800 mg/day thereafter)
while the other 5 patients showed a complete cytogenetic
response at 12 months. In every case, we examined the
sample at diagnosis and twelve months after treatment
with IM for the presence of the clinically significance
mutations T315I, Y253H, Y253F, E225K and E255V using
allele-specific oligonucleotide polymerase chain reaction
(ASO-PCR), and none of these mutations was detected
(data not shown). All studies were approved by the
Research Review Boards at the University of Navarra.
Informed consent was obtained from all the patients.
RNA extraction of nucleated cells and reverse transcrip-
tion were carried out as described [3]. Briefly, total RNA
was extracted with Ultraspec (Biotecx, Houston, TX, USA)
following the manufacturer's instructions. 5 ng of total
RNA was used to synthesize a specific cDNA of each ana-
lyzed miRNA using stem-loop miRNA-specific RT primer,
according to the TaqMan MicroRNA Assay protocol
(Applied Biosystems, Foster City, CA). Expression of 250
miRNAs was analyzed using specific primers and TaqMan
probe for each miRNA according to the TaqMan Micro-
RNA Assay Protocol (Applied Biosystems, Foster City,
CA). Q-RT-PCR was performed using an Applied Biosys-
tems 7300 Sequence Detection system as described [3].
Expression of miRNA was normalized using the expres-
sion of the housekeeping gene RNU6B. Expression of
miRNAs in every patient is included in the Additional file
1. Relative quantification of expression of analyzed miR-
NAs was calculated with the 2-ΔΔCt method (Applied Bio-
systems. User Bulletin N°2 (P/N 4303859)). Data are
presented as log 2-ΔΔCt of the relative quantity of miRNAs,
normalized and compared with the expression in samples
obtained from patients that responded to IM. A super-
vised analysis using the SAM algorithm (Significant Anal-
ysis of Microarrays) was performed in order to identify
miRNAs with statistically significant changes in expres-
sion between both groups.
Using both methods, relative quantification and super-
vised analysis, we identified 19 miRNAs differentially
expressed between resistant and responder samples: 18 of
them were down-regulated (hsa-miR-7, hsa-miR-23a, hsa-
miR-26a, hsa-miR-29a, hsa-miR-29c, hsa-miR-30b, hsa-miR-
30c, hsa-miR-100, hsa-miR-126#, hsa-miR-134, hsa-miR-
141, hsa-miR-183, hsa-miR-196b, hsa-miR-199a, hsa-miR-
224, hsa-miR-326, hsa-miR-422b and hsa-miR-520a) and
only one was up-regulated (hsa-miR-191) in resistant CML
patients. To demonstrate whether this set of miRNAs may
classify properly both groups, we performed an unsuper-
vised cluster analysis using Genesis software using the
results obtained with the 8 patients included in the analy-
sis. Hierarchical clustering based on the average-linkage
method with the centered correlation metric was used.
The cluster unsupervised analysis based on differentially
expressed miRNAs generated a tree that clearly separates
both groups (Figure 1) suggesting that this miRNA profile
could distinguish the IM-response in CML patients.
In order to determine potential genes and signaling path-
ways implicated in resistance to IM, we analyzed pre-
dicted targets of the 19 miRNAs differentially expressed
using four different algorithms (mirBase, miRanda, Tar-
getScan and PicTar). Because each of the four approaches
generated an unpredictable number of false positives,
results were intersected to identify the genes commonly
predicted by at least three of the algorithms. Among allPage 2 of 4
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membrane transporters that belong to the ATP binding
cassette (ABC) superfamily of transmembrane transport-
ers, which have been implicated in resistance to chemo-
therapy. These transporters are ABCC5, ABCA1 and
ABCB6, potential targets of hsa-miR-199a, hsa-miR-183
and hsa-miR-29c respectively. Our own unpublished stud-
ies indicate that up-regulation of ABCA1 is observed in
CML patients that develop resistance to IM (data not
shown), suggesting that alterations of ABC transporters
mediated by miRNAs might be a mechanism of resistance
to IM. Other targets of the differentially expressed miR-
NAs such as RAB11A (possible target of hsa-miR-520a) or
SIRT1 (possible target of hsa-miR-199a) have recently
been implicated in resistance to IM [10,11].
In conclusion, we identify a group of 19 miRNAs that may
predict clinical resistance to IM in patients with newly
diagnosed CML. Further studies are nevertheless required
to validate the role of these miRNAs as predictors for
resistance to IM and to identify miRNAs targets and their
function in resistance to IM in CML.
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Hierarchical cluster analysis of miRNA expression in resist-ant and responder CML patientsFigure 1
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of expression of the 19 miRNAs differentially expressed 
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